U.S. HHS Awards 10-Year, $2B Contract To Emergent BioSolutions For Smallpox Vaccine For National Stockpile

Homeland Preparedness News: HHS awards 10-year contract to Emergent BioSolutions for smallpox vaccine
“Emergent BioSolutions Inc. said Tuesday it was awarded a contract for its smallpox vaccine from the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years. The contract specifically supports the continued supply of Emergent’s ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS)…” (Flax, 9/3).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.